MorphoSys Hits Refresh Button On Pipeline With Constellation Buy

Deal Worth $1.7bn Financed Through $2bn Partnership With Royalty

The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.

Businessman and Businesswoman pressing Refresh Button
MorphoSys said 2 June it would acquire Constellation Pharmaceuticals for $1.7bn • Source: Shutterstock

Already looking at ways to expand to compete with major players in biotech after the launch of its first product in the US, European biotech MorphoSys AG is beefing up its pipeline with two mid- and late-stage epigenetic compounds with the $1.7bn acquisition of Constellation Pharmaceuticals, Inc.. The deal, which includes a novel financing partnership with Royalty Pharma plc, may also portend a pickup in the speed of M&A for 2021.

MorphoSys, based near Munich, Germany, and Cambridge, MA-based Constellation announced the $34-per-share deal on 2 June, which both companies’ boards...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By 

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

More from Business

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By 

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.